acetazolamide will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Addressing Concerns and FAQs: Key Insights on Vardenafil
selpercatinib increases toxicity of vardenafil by QTc interval. Coadministration of sepiapterin with drugs affecting nitric oxide-mediated relaxation may cause additive vasodilation and further reduce blood pressure. sertralinesertraline and vardenafil both increase QTc interval. sertraline and vardenafil both increase QTc interval. Consider predose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.
4.3 Comparison with Other PDE5 Inhibitors and Formulations
sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of vardenafil by QTc interval. sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of vardenafil by QTc interval. solifenacinsolifenacin and vardenafil both increase QTc interval. solifenacin and vardenafil both increase QTc interval. sorafenibsorafenib and vardenafil both increase QTc interval. anastrozoleanastrozole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. anastrozole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. azithromycinazithromycin increases toxicity of vardenafil by QTc interval. azithromycin increases toxicity of vardenafil by QTc interval.
| Medication Class | Interaction Effect | Precaution |
|---|---|---|
| Nitrates | Severe hypotension | Avoid concurrent use |
| Alpha-blockers | Additive blood pressure lowering | Use with caution |
| CYP3A4 inhibitors | Increased vardenafil levels | Dose adjustment needed |
| Grapefruit juice | Increased absorption | Avoid during therapy |
carvedilolvardenafil increases effects of carvedilol by pharmacodynamic synergism. vardenafil increases effects of carvedilol by pharmacodynamic synergism.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Kamagra Gold | 100 mg | 12 Pills | 55.64€ 52.99€ | |
| Kamagra Gold | 100 mg | 120 + 6 Pills | 330.74€ 314.99€ | |
| Levitra Professional | 20mg | 30 Pills | 119.12€ 113.45€ | |
| Kamagra Soft Tabs | 100 mg | 60 + 4 Pills | 180.59€ 171.99€ | |
| Viagra Original | 100mg | 48 + 4 Pills | 207.15€ 197.29€ | |
| Kamagra | 100mg | 180 + 6 Pills | 436.79€ 415.99€ | |
| Viagra Soft Tabs | 100mg | 10 Pills | 36.93€ 35.17€ | |
| Levitra Original | 20mg | 34 + 2 Pills | 188.51€ 179.53€ | |
| Viagra Oral Jelly | 100mg | 21 Sachets | 78.66€ 74.91€ | |
| Levitra Generic | 10mg | 10 Pills | 28.93€ 27.55€ | |
| Levitra Generic | 40mg | 90 + 6 Pills | 234.73€ 223.55€ |
chloroquinechloroquine increases toxicity of vardenafil by QTc interval.
- Vardenafil dosage adjustments may be needed for older adults.
- It may pose risks in men with low blood pressure.
- Always adhere to the prescribed therapeutic regimen.
- It is not recommended to exceed 20 mg per dose.
- Vardenafil is not intended for use with other ED medications.
- Precise timing of doses ensures efficacy and safety.
- The drug may improve sexual confidence and satisfaction.
- Side effects are usually temporary and dose-related.
- Alcohol and high-fat foods can delay onset of action.
- Avoid using Vardenafil if allergies to it are known.
- Proper hydration can enhance its effectiveness.
chloroquine increases toxicity of vardenafil by QTc interval. cyclophosphamidecyclophosphamide will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Product Overview
Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. sunitinibsunitinib and vardenafil both increase QTc interval. sunitinib and vardenafil fildena purple pill both increase QTc interval. suzetriginesuzetrigine decreases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor patients for loss of therapeutic effect of sensitive CYP3A substrates with narrow therapeutic indexes when coadministered with suzetrigine.
Our Services
Consider modifying dose of sensitive substrate according to prescribing recommendations. suzetrigine decreases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Concomitant use may increase the risk of QTc interval prolongation. If concomitant use is unavoidable, adjust the frequency of ECG and electrolyte monitoring. tecovirimattecovirimat will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cyclophosphamide will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
What side effects can this medication cause?
rifapentine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rilzabrutinibrilzabrutinib increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Reduce vardenafil dose if coadministered with moderate CYP3A inhibitors. rilzabrutinib increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ritonavirritonavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Who should not take vardenafil?
Adjust dosage of CYP3A4 substrates, if clinically indicated. rucaparib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rufinamiderufinamide will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rufinamide will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. selpercatinibselpercatinib increases toxicity of vardenafil by QTc interval. drospirenonedrospirenone will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. drospirenone will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Alcohol/Food Interaction
verapamilverapamil will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors verapamil will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors Either increases effects of the other by QTc interval. voriconazolevoriconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose sex erection tablet may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors voriconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
3.2 Administration Guidelines
Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors vorinostatvorinostat and vardenafil both increase QTc interval. vorinostat and vardenafil both increase QTc interval. zafirlukastzafirlukast will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. zafirlukast will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. acetazolamideacetazolamide will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. labetalolvardenafil increases effects of labetalol by pharmacodynamic synergism.
- Vardenafil enhances blood flow to the penis.
- It is sold under brand names like Levitra and Staxyn.
- The drug is generally well-tolerated when used correctly.
- Common side effects include dizziness and nasal congestion.
- It should be stored in a cool, dry place away from children.
- Vardenafil is not an aphrodisiac; it requires sexual stimulation.
- Excessive doses can increase cardiovascular risks.
- It’s important to follow the doctor’s instructions for use.
- Patients with heart conditions should consult a doctor before use.
- Vardenafil may cause visual disturbances in some people.
- Regular medical review is recommended during treatment.
vardenafil increases effects of labetalol by pharmacodynamic synergism.
Initial Information
Monitor sensitive CYP3A4 substrates for effectiveness if coadministered. tecovirimat will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tetracyclinetetracycline will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors tetracycline will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors tobramycin inhaledtobramycin inhaled and vardenafil both increase nephrotoxicity and/or ototoxicity.
Less common
Avoid concurrent or sequential use to decrease risk for ototoxicity tobramycin inhaled and vardenafil both increase nephrotoxicity and/or ototoxicity. Avoid concurrent or sequential use to decrease risk for ototoxicity topiramatetopiramate will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. topiramate will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. valbenazinevalbenazine and vardenafil sex tablet women both increase QTc interval. valbenazine and vardenafil both increase QTc interval. Possible additive vasorelaxation, leading to low blood pressure. Soluble guanylate cyclase (sGC) stimulators (eg, riociguat); concomitant use can cause hypotension Coadministration with nitrates (either regularly and/or intermittently) and nitric oxide donors Consistent with the effects of PDE5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, PDE5 inhibitors may potentiate the hypotensive effects of nitrates A suitable time interval following PDE5 dosing for the safe administration of nitrates or nitric oxide donors has not been determined Use with caution in anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie’s disease), cardiovascular disease, left ventricular outflow obstruction, bleeding disorders, active peptic ulcer disease, liver disease, renal impairment, multidrug antihypertensive regimens, retinitis pigmentosa, concomitant use of CYP3A4 inhibitors, patients who have conditions that may predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia) There have been rare reports of prolonged erections >4 hr and priapism (painful erections greater than 6 hours in duration) for this class of compounds, including vardenafil; in the event that an erection persists >4 hours, the patient should seek immediate medical assistance; if priapism is not treated immediately, penile tissue damage and permanent loss of potency may result Physicians should consider the cardiovascular status of their patients; there is a degree of cardiac risk associated with sexual activity; treatment for erectile dysfunction, should not be used in men for whom sexual activity is not recommended because of their underlying cardiovascular status Patients with left ventricular outflow obstruction, (for example, aortic stenosis and idiopathic hypertrophic subaortic stenosis) can be sensitive to the action of vasodilators including PDE5 inhibitors Until further information available, use is not recommended in unstable angina; hypotension (resting systolic blood pressure of <90 mmHg); uncontrolled hypertension (>170/110 mmHg); recent history of stroke, life-threatening arrhythmia, or myocardial infarction (within last 6 months); severe cardiac failure Consider counseling patients about protective measures necessary to guard against sexually transmitted diseases, including Human Immunodeficiency Virus (HIV); drug offers no protection against sexually transmitted diseases Patients taking Class 1A (eg, quinidine, procainamide) or Class III (eg, amiodarone, sotalol) antiarrhythmic medications or those with congenital QT prolongation, should avoid using drug Safety and efficacy of drug used in combination with other treatments for erectile dysfunction not studied; use of such combinations not recommended Vision loss may occur rarely and may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION); patient should seek medical assistance for sudden loss in one or both eyes; patients who have already experienced NAION are at increased risk of recurrence; use is not recommended in patients with known degenerative retinal disorders May increase risk of rare sudden vision loss attributed to nonarteritic ischemic optic neuropathy; if vision problems arise, discontinue, and contact physician The drug has systemic vasodilatory properties that resulted in transient decreases in supine blood pressure in healthy volunteers (mean maximum decrease of 7 mmHg systolic and 8 mmHg diastolic); while this normally would be expected to be of little consequence in most patients, physicians should carefully consider whether their patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects Physicians should advise patients to stop taking all PDE5 inhibitors, and seek prompt medical attention in event of sudden decrease or loss of hearing; these events, which may be accompanied by tinnitus and dizziness, have been reported in temporal association to intake of PDE5 inhibitors, including vardenafil; it is not possible to determine whether these events are related directly to use of PDE5 inhibitors or to other factors CYP3A4 inhibitorsConcomitant administration with potent CYP3A4 inhibitors (eg, ritonavir, indinavir, cobicistat, ketoconazole) or moderate CYP3A4 inhibitors (eg, erythromycin) increases plasma concentrations of drug; dosage adjustment is necessary when drug is administered with certain CYP3A4 inhibitorsLong-term safety information is not available on concomitant administration of drug with HIV protease inhibitors Concomitant administration with potent CYP3A4 inhibitors (eg, ritonavir, indinavir, cobicistat, ketoconazole) or moderate CYP3A4 inhibitors (eg, erythromycin) increases plasma concentrations of drug; dosage adjustment is necessary when drug is administered with certain CYP3A4 inhibitors Long-term safety information is not available on concomitant administration of drug with HIV protease inhibitors Alpha blockersCaution advised when PDE5 inhibitors co-administered with alpha-blockers; PDE5 inhibitors, and alpha-adrenergic blocking agents are both vasodilators with blood-pressure lowering effects; when vasodilators are used in combination, an additive effect on blood pressure may be anticipated; in some patients, concomitant use of these two drug classes can lower blood pressure significantly leading to symptomatic hypotension (eg, fainting)Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor; patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitorsIn patients who are stable on alpha-blocker therapy, initiate PDE5 inhibitors at lowest recommended starting doseIn patients already taking optimized dose of PDE5 inhibitor, initiate alpha-blocker therapy at lowest dose; stepwise increase in alpha-blocker dose may be a
| Drug | Efficacy Rate | Duration of Action | Note |
|---|---|---|---|
| Vardenafil | ~75-80% | 4-5 hours | Similar to other PDE5 inhibitors |
| Sildenafil | ~70-75% | 4-6 hours | Most commonly prescribed |
| Tadalafil | ~80-85% | Up to 36 hours | Longer duration, suitable for daily use |
| Avanafil | ~75% | 4-6 hours | Fast onset, quick clearing from system |